Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 3/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29357331 | 0.93 | MAPT (0.69) | MAPTLMNABAZ2BTRPV1ALDH1A1 | |
| SCHEMBL2241936 | 0.93 | MAPT (0.69) | MAPTLMNABAZ2BTRPV1ALDH1A1 | |
| Acetic Acid SCHEMBL8714196 | 0.90 | MAPT (0.68) | MAPTLMNABAZ2BTRPV1ALDH1A1 | |
| SCHEMBL21154454 | 0.87 | LMNA (0.55) | MAPTLMNABAZ2BTRPV1FAAH | |
| SCHEMBL350201 | 0.86 | TRPV1 (0.69) | MAPTLMNABAZ2BTRPV1FAAH | |
| SCHEMBL10127719 | 0.85 | LMNA (0.66) | MAPTLMNABAZ2BALDH1A1KDM4E | |
| SCHEMBL1006826 | 0.84 | BAZ2B (0.51) | MAPTLMNABAZ2BALDH1A1KDR | |
| SCHEMBL10127727 | 0.84 | BAZ2B (0.62) | MAPTLMNABAZ2BALDH1A1KDM4E | |
| SCHEMBL6474214 | 0.84 | LMNA (0.60) | MAPTLMNABAZ2BTRPV1KDM4E | |
| Acetic Acid SCHEMBL8718251 | 0.83 | TRPV1 (0.68) | MAPTLMNABAZ2BTRPV1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2637503-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2013-09-18 | — | — | EP | claimed |
| WO-2012064680-A1 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2012-05-18 | — | — | WO | claimed |
| EP-2062895-A1 | SUBSTITUTED AZEPINO[4,3-B]INDOLES, PHARMACOLOGICAL COMPOSITION AND A METHOD FOR THE PRODUCTION AND USE THEREOF | Alla Chem, LLC. (US) | 2009-05-27 | — | — | EP | claimed |
| US-20120040965-A1 | SUBSTITUTED AZEPINO[4,3-B]INDOLES, PHARMACOLOGICAL COMPOSITION AND A METHOD FOR THE PRODUCTION AND USE THEREOF | BORISOVICH FROLOV YEVGENIY (RU) | 2012-02-16 | — | — | US | disclosed |
| US-20120040965-A1 | SUBSTITUTED AZEPINO[4,3-B]INDOLES, PHARMACOLOGICAL COMPOSITION AND A METHOD FOR THE PRODUCTION AND USE THEREOF | BORISOVICH FROLOV YEVGENIY (RU) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040965-A1 | SUBSTITUTED AZEPINO[4,3-B]INDOLES, PHARMACOLOGICAL COMPOSITION AND A METHOD FOR THE PRODUCTION AND USE THEREOF | ABCG2, HTR3C, AADAC | MAPT 4749/4885LMNA 2065/4885BAZ2B 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.